Vapotherm, Inc. (VAPO)
USD 2.17
(-0.46%)
USD 2.17
(-0.46%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 28.28 Million USD | 64.03% |
| 2022 | 17.24 Million USD | -67.58% |
| 2021 | 53.18 Million USD | -15.64% |
| 2020 | 63.04 Million USD | 195.84% |
| 2019 | 21.31 Million USD | 27.06% |
| 2018 | 16.77 Million USD | 26.68% |
| 2017 | 13.24 Million USD | 33.21% |
| 2016 | 9.93 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 8.28 Million USD | -14.23% |
| 2024 Q1 | 9.65 Million USD | 4.99% |
| 2023 Q4 | 9.19 Million USD | 52.97% |
| 2023 Q2 | 6.86 Million USD | 10.43% |
| 2023 Q1 | 6.21 Million USD | 21.26% |
| 2023 Q3 | 6.01 Million USD | -12.35% |
| 2023 FY | 28.28 Million USD | 64.03% |
| 2022 Q4 | 5.12 Million USD | 174.99% |
| 2022 Q1 | 7.89 Million USD | 1.32% |
| 2022 FY | 17.24 Million USD | -67.58% |
| 2022 Q2 | 2.36 Million USD | -70.03% |
| 2022 Q3 | 1.86 Million USD | -21.23% |
| 2021 FY | 53.18 Million USD | -15.64% |
| 2021 Q3 | 18.82 Million USD | 100.11% |
| 2021 Q2 | 9.4 Million USD | -45.21% |
| 2021 Q1 | 17.16 Million USD | -17.11% |
| 2021 Q4 | 7.78 Million USD | -58.62% |
| 2020 FY | 63.04 Million USD | 195.84% |
| 2020 Q4 | 20.71 Million USD | 33.53% |
| 2020 Q1 | 9.21 Million USD | 57.21% |
| 2020 Q3 | 15.51 Million USD | -11.92% |
| 2020 Q2 | 17.6 Million USD | 91.04% |
| 2019 Q1 | 5.17 Million USD | 7.49% |
| 2019 Q4 | 5.86 Million USD | 21.89% |
| 2019 Q3 | 4.81 Million USD | -11.89% |
| 2019 Q2 | 5.45 Million USD | 5.41% |
| 2019 FY | 21.31 Million USD | 27.06% |
| 2018 Q2 | 4.09 Million USD | -3.53% |
| 2018 FY | 16.77 Million USD | 26.68% |
| 2018 Q4 | 4.81 Million USD | 33.31% |
| 2018 Q1 | 4.24 Million USD | 22.69% |
| 2018 Q3 | 3.61 Million USD | -11.75% |
| 2017 Q3 | 2.78 Million USD | -17.17% |
| 2017 Q4 | 3.46 Million USD | 24.33% |
| 2017 FY | 13.24 Million USD | 33.21% |
| 2017 Q1 | 3.49 Million USD | 0.0% |
| 2017 Q2 | 3.36 Million USD | -3.96% |
| 2016 FY | 9.93 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Abbott Laboratories | 22.13 Billion USD | 99.872% |
| Allurion Technologies Inc. | 41.49 Million USD | 31.843% |
| Artivion, Inc. | 229.17 Million USD | 87.659% |
| Avanos Medical, Inc. | 379.7 Million USD | 92.551% |
| Butterfly Network, Inc. | 16.85 Million USD | -67.792% |
| Butterfly Network, Inc. | 16.85 Million USD | -67.792% |
| Bio-Rad Laboratories, Inc. | 1.43 Billion USD | 98.024% |
| Boston Scientific Corporation | 9.89 Billion USD | 99.714% |
| Perspective Therapeutics, Inc. | 1.63 Million USD | -1630.906% |
| CONMED Corporation | 643.06 Million USD | 95.602% |
| Edwards Lifesciences Corporation | 4.62 Billion USD | 99.388% |
| Paragon 28, Inc. | 172.79 Million USD | 83.632% |
| Glaukos Corporation | 239.13 Million USD | 88.173% |
| Globus Medical, Inc. | 1.02 Billion USD | 97.228% |
| Inspire Medical Systems, Inc. | 528.22 Million USD | 94.646% |
| Integer Holdings Corporation | 418.28 Million USD | 93.238% |
| Medtronic plc | 19.45 Billion USD | 99.855% |
| Nevro Corp. | 290.06 Million USD | 90.249% |
| Owlet, Inc. | 22.58 Million USD | -25.218% |
| Penumbra, Inc. | 682.64 Million USD | 95.857% |
| Vicarious Surgical Inc. | -1.85 Million USD | 1625.512% |
| Smith & Nephew plc | 3.7 Billion USD | 99.236% |
| Sonendo, Inc. | 10.72 Million USD | -163.785% |
| STERIS plc | 2.23 Billion USD | 98.734% |
| Stryker Corporation | 13.05 Billion USD | 99.783% |
| Zimmer Biomet Holdings, Inc. | 5.31 Billion USD | 99.467% |